Table 3.

Findings regarding cancer sites previously associated with the drugs studied. Two-year lag, three or more dispensings.

Drug	Cancer site	No. exposed cases	Odds ratio (95% confidence interval) [sensitivity limits]*
Chloramphenicol	Leukemia, any type	0	--
Cyclophosphamide	Urinary bladder	12	2.76 (1.45–5.25) [2.30–3.22]
	Myeloid leukemia	5	4.17 (1.47–11.83) [3.47–4.87]
	Other leukemia	1	10.00 (1.63–159.9) [8.32–11.68]
Griseofulvin	Liver, intrahepatic bile ducts	2	0.91 (0.21–3.87) [0.76–1.06]
	Breast	35	1.59 (1.11–2.27) [1.32–1.86]
	Thyroid	1	0.50 (0.07–3.73) [0.42–0.58]
Iron-dextran complex	Soft tissue, heart	0	--
Metronidazole	Colon	120	0.80 (0.66–0.97) [0.67–0.93]
	Liver, intrahepatic bile ducts	17	0.88 (0.53–1.45) [0.73–1.03]
	Lung, bronchus	226	0.93 (0.81–1.06) [0.54–1.09]
	Breast	498	1.13 (1.02–1.24) [0.94–1.32]
	Cervix uteri	16	0.87 (0.52–0.1.47) [0.72–1.05]
	Testis	1	0.59 (0.08–4.44) [0.49–0.69]
	Other endocrine, thymus	3	1.89 (0.54–6.68) [1.57–2.21]
	Non-Hodgkin lymphoma	84	1.06 (0.84–1.33) [0.88–1.24]
Oxazepam	Liver, intrahepatic bile ducts	10	1.48 (0.76–2.89) [1.23–1.72]
	Thyroid	9	1.68 (0.83–3.42) [1.40–1.96]
Phenobarbital	Gallbladder	1	0.57 (0.07–4.34) [0.47–0.67]
	Lung, bronchus	92	1.01 (0.82–1.26) [0.59–1.18]
	Ovary	16	1.08 (0.64–1.82) [0.90–1.26]
	Brain	9	1.15 (0.58–2.31) [0.96–1.34]
Phenoxybenzamine	Peritoneum, omentum, mesentery	0	--
	Lung, bronchus	5	1.62 (0.63–4.16) [0.95–1.89]
Phenytoin	Esophagus	15	2.54 (1.44–4.51) [2.11–2.97]
	Liver, intrahepatic bile ducts	15	1.66 (0.96–2.88) [1.38–1.94]
	Lung, bronchus	126	1.51 (1.25–1.82) [0.88–1.76]
	Breast	81	1.02 (0.81–1.28) [0.85–1.19]
	Non-Hodgkin lymphoma	27	0.96 (0.65–1.43) [0.80–1.12]
	Lymphocytic leukemia	11	1.91 (1.00–3.64) [1.59–2.23]
Propylthiouracil	Thyroid	3	2.79 (0.78–10.02) [2.32–3.26]
	Other endocrine	0	--

^*Sensitivity analysis limits: odds ratio decreased and increased by 16.8% except lung cancer decreased by 41.6% (see text for assumptions).